Copyright
©The Author(s) 2021.
World J Stem Cells. Apr 26, 2021; 13(4): 236-259
Published online Apr 26, 2021. doi: 10.4252/wjsc.v13.i4.236
Published online Apr 26, 2021. doi: 10.4252/wjsc.v13.i4.236
Table 1 Summary of landmark human clinical trials
Cell type | Clinical trial | Sample size | Results | Ref. |
ESCs | ESCORT | 6 | Improvement in NYHA functional class, 6 min test and heart wall motion | [32] |
iPSCs | Cyranoski, 2018 | 10 | Trial results pending | [36] |
HEAL-CHF | 5 | Trial results pending | [36] | |
CSCs | CADUCEUS | 31 | Improvements in scar size, regional contractility and heart mass; no differences in EDV, ESV and LVEF between groups | [42] |
BMMNCs | Perin et al[44], 2003 | 21 | Improvements in LVEF, perfusion and contractility; Reductions in ESV | [44] |
TOPCARE-CHD | 121 | Improvements in global cardiac function and contractility, decreased BNP and mortality | [45] | |
STAR-heart; | 191 | Improvements in LVEF, NYHA functional class and long-term mortality; Decreased LV preload, ESV and infarct area | [46] | |
FOCUS-CCTRN | 92 | No improvements in LVEF, maximal O2 consumption and infarct size | [47] | |
BMMNCs and autologous MSCs | TAC-HFT | 65 | Decreased infarct size and improvements in 6 min walk test and regional function of the heart in MSC group only | [49] |
CD133(+) | CARDIO33 | 60 | No improvements in LV function or clinical symptoms | [50] |
BMDSCs | Systematic review and meta-analysis | 1907 | Low-quality evidence that BMDSCs reduce mortality, improves LVEF and improves NYHA functional class | [51] |
Autologous MSCs | MSC-HF | 60 | Improvements in LVEF, stroke volume and myocardial mass | [54] |
Autologous and allogeneic MSCs | POSEIDON | 30 | Improvements in LV functions with reductions in adverse remodeling, infarct size | [55] |
POSEIDON-DCM | 37 | Greater improvements seen in allogeneic MSCs regarding functional capacity, quality of life, EF, 6 min walk test, and the Minnesota Living with HF questionnaire | [56] | |
Cardiopoietic | C-CURE | 36 | Improvements in LVEF, quality of life and decreased LVESV | [57] |
CHART-1 | 351 | Decreased LVESV and LVEDV | [58] | |
Umbilical MSCs | RIMECARD | 30 | Improvements in LVEF but no improvements in LVESV or LVEDV | [60] |
Zhao et al[61], 2015 | 59 | No improvements in LVEF but some improvements in the 6 min walk test, mortality rate and NT-pro brain natriuretic peptide levels | [61] | |
MPCs | DREAM-HF-1 | 566 | Trial results pending | [64] |
MSCs | Systematic review and meta-analysis | 29 studies | Improvements in LVEF, LVESV, NYHA functional class, quality of life and exercise capacity | [65] |
Systematic review and meta-analysis | 12 studies | No significant improvements in LVEF. Improvements in quality of life and the 6 min walk test | [52} | |
SMs | MAGIC | 120 with 7 patients on f/u | No improvements in LVEF or global heart function | [68,69] |
MARVEL | 23 | No improvements in LV function; Moderate improvements in 6 min walk test | [71] |
- Citation: Rheault-Henry M, White I, Grover D, Atoui R. Stem cell therapy for heart failure: Medical breakthrough, or dead end? World J Stem Cells 2021; 13(4): 236-259
- URL: https://www.wjgnet.com/1948-0210/full/v13/i4/236.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i4.236